SiBone (NASDAQ:SIBN) Insider Sells $112,353.85 in Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 5,747 shares of SiBone stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $19.55, for a total transaction of $112,353.85. Following the sale, the insider owned 246,148 shares in the company, valued at approximately $4,812,193.40. This represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The shares were sold at an average price of $18.65, for a total value of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total value of $55,626.09.

SiBone Price Performance

SiBone stock opened at $19.96 on Monday. The stock’s 50 day moving average is $17.49 and its 200 day moving average is $15.32. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The firm has a market cap of $885.21 million, a P/E ratio of -58.71 and a beta of 0.66. SiBone has a one year low of $11.48 and a one year high of $21.89.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. As a group, research analysts expect that SiBone will post -0.4 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Truist Financial reaffirmed a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, UBS Group increased their price objective on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, SiBone has an average rating of “Moderate Buy” and a consensus price target of $24.17.

Hedge Funds Weigh In On SiBone

Several large investors have recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd bought a new stake in SiBone in the 4th quarter worth about $29,000. Royal Bank of Canada grew its holdings in shares of SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of SiBone during the fourth quarter valued at approximately $53,000. 98.11% of the stock is currently owned by institutional investors.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.